Update on first-line treatment of advanced ovarian carcinoma
Z Kemp,1 JA Ledermann1,21Department of Oncology, University College London Hospitals, 2University College London Cancer Institute, University College London, London, United KingdomAbstract: Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patien...
Saved in:
Main Authors: | Kemp Z (Author), Ledermann JA (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
by: Ying He, et al.
Published: (2023) -
Histopathological Efficacy of Docetaxel Versus Paclitaxel As First Line Chemotherapy for Epithelial Ovarian Carcinoma
by: Tayyup Şimşek, et al.
Published: (2008) -
Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
by: Georges Gebrael, et al.
Published: (2023) -
Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
by: Zhiwei Zheng, et al.
Published: (2024) -
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
by: Sujin Jin, et al.
Published: (2023)